Liver problems with Abbott Laboratories Inc.’s discontinued attention deficit drug Cylert and other generic versions are too dangerous for the U.S. market, the Food and Drug Administration said on Monday.
“The agency has concluded that the overall risk of liver toxicity from Cylert and generic pemoline products outweighs the benefits of this drug,” the FDA said in a warning posted on its Web site.
In March, Abbott said it would no longer make the drug due to declining sales, but consumer advocates had argued it was too dangerous to be sold.
Dr. John Grohol is the CEO and founder of Psych Central. He is an author, researcher and expert in mental health online, and has been writing about online behavior, mental health and psychology issues -- as well as the intersection of technology and human behavior -- since 1992. Dr. Grohol sits on the editorial board of the journal Cyberpsychology, Behavior and Social Networking and is a founding board member and treasurer of the Society for Participatory Medicine.Like this author?
Catch up on other posts by John M. Grohol, PsyD (or subscribe to their feed).
Comments
This post currently has 2 comments. You can read the comments or leave your own thoughts on our new comments page.
Trackbacks
No trackbacks yet to this post.
Last reviewed: By John M. Grohol, Psy.D. on 24 Oct 2005
Published on PsychCentral.com. All rights reserved.
APA Reference
Grohol, J. (2005). Discontinued ADD drug too risky: FDA. Psych Central. Retrieved on February 14, 2012, from http://psychcentral.com/blog/archives/2005/10/24/discontinued-add-drug-too-risky-fda/
Grohol, J. (2005). Discontinued ADD drug too risky: FDA. Psych Central. Retrieved on February 14, 2012, from http://psychcentral.com/blog/archives/2005/10/24/discontinued-add-drug-too-risky-fda/
